A novel clinical trial is investigating the safety and efficacy of using low-intensity focused ultrasound (LIFU) neuromodulation in patients with generalized anxiety disorder.
The Virginia Tech Accelerated Holographic LIFU for Anxiety (VITAL) trial (NCT07404878), led by Wynn Legon, PhD, assistant professor at the Fralin Biomedical Research Institute at VTC in Roanoke, Virginia, uses image-guided ultrasound to target the anterior insula, a brain region involved in anxiety. The approach combines multiple ultrasound applications within a single treatment session with customized, 3D-printed acoustic lenses that tailor ultrasound targeting to each participant’s unique brain anatomy. The trial will test whether this approach can safely reduce anxiety and produce lasting benefits.
The trial will enroll 50 participants assigned to lower- or higher-dose low-intensity focused ultrasound (LIFU). Each participant will receive one active treatment session and one sham session in randomized order, approximately four weeks apart.
At-home questionnaires and in-person assessments will track changes in anxiety during follow-up. The team will also monitor safety and changes in heart rate, respiratory rate, and blood pressure.
After more than a decade studying low-intensity focused ultrasound, I’m excited to combine an accelerated treatment protocol with personalized, 3D-printed lenses to precisely target brain regions involved in anxiety. We hope this trial will move us closer to an effective, affordable treatment option for people who do not find relief with medication.”
Wynn Legon, PhD, assistant professor, Fralin Biomedical Research Institute at VTC in Roanoke, Virginia
To date, 18 participants have enrolled, six of whom have completed the study. The Focused Ultrasound Foundation is funding this clinical trial.
Source:
